Welcome to
Chiesi group
At Chiesi, our portfolio and pipeline are focused on developing and bringing to market innovative pharmaceutical solutions that improve the quality of people's lives, with a strong focus on four core therapeutic areas: respiratory, rare diseases, neonatology, and special care.
In 2024, R&D spending reached a record 24.3% of revenue, highlighting the strategic importance and productivity of our R&D efforts. This includes both development (clinical research aimed at registering new drugs) and applied research (identifying new chemical entities, biological entities, or different therapeutic solutions).
Additionally, 33 patent applications were filed with the European Patent Office (EPO), further demonstrating our commitment to innovation. According to the JRC EU Industrial R&D Investment Scoreboard 2024, Chiesi remained the top pharmaceutical company in Italy for R&D investments and the 11th in Europe.
